期刊首页 优先出版 当期阅读 过刊浏览 作者中心 关于期刊 English

2019年 第13卷 第4期

摘要

关键词

相关研究

回顶部

《医学前沿（英文）》 >> 2019年 第13卷 第4期 doi: 10.1007/s11684-018-0672-6

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Hepato–Pancreato–Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China

录用日期： 2019-02-22 发布日期： 2019-02-22
HTML19 PDF 1 收藏 0

下一篇 上一篇

摘要

Desmoid-type fibromatosis (DF) is a rare monoclonal fibroblastic proliferation that is characterized by locally infiltrative but rarely metastatic lesions. Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF. The use of these drugs, however, is mainly based on the recommendations of retrospective studies with small sample sizes. Previous studies that focused on the mechanism, efficacy, and safety of targeted therapy for DF were reviewed to provide references for clinical applications and research. The efficacy and safety of targeted therapy were compared with those of other systemic therapy options. Targeted therapy does not provide considerable advantages in efficacy and safety over other medical treatments and is usually applied after the failure of antihormonal therapies, nonsteroidal anti-inflammatory drugs, and chemotherapy. Further studies are required to explore the mechanism, indications, and appropriate drug dosage of the targeted therapy of DF.

相关研究